Recommended CME For You +++ +++ +++

The Road to Biosimilars in Rare Hematologic Conditions CME The Road to Biosimilars in Rare Hematologic Conditions Authors: Srikanth Nagalla, MD, MS https://www.medscape.org/viewarticle/1001793?sso=true&uac=148436CN&src=mkmcmr_driv_invit_mscpedu Guiding Our Patient's Path: Managing First Relapse in Diffuse Large B-Cell Lymphoma Outside of CAR Ts CME Guiding Our Patient's Path: Managing First Relapse in Diffuse Large B-Cell Lymphoma Outside of CAR Ts Authors: Wendy Osborne, MBBS (Hons), MRCP, FRCPath; Natacha Bolaños; Gareth Gregory, MBBS, PhD; Gilles Salles, MD, PhD https://www.medscape.org/viewarticle/1002120?sso=true&uac=148436CN&src=mkmcmr_driv_invit_mscpedu Expert Interview: Best Practices for AL Amyloidosis Management in the Community CME Expert Interview: Best Practices for AL Amyloidosis Management in the Community Authors: Shahzad Raza, MD, FACP https://www.medscape.org/viewarticle/expert-interview-best-practices-al-amyloidosis-management-2025a10002fg?page=1&sso=true&uac=148436CN&src=mkmcmr_driv_invit_mscpedu Which Patients With HR+/HER2- EBC Benefit From Intensification of Therapy? Expert Recommendations for Clinical Assessment CME Which Patients With HR+/HER2- EBC Benefit From Intensification of Therapy? Expert Recommendations for Clinical Assessment Authors: Joyce A. O’Shaughnessy, MD https://www.medscape.org/viewarticle/which-patients-hr-her2-ebc-benefit-intensification-therapy-2025a10002qz?page=1&sso=true&uac=148436CN&src=mkmcmr_driv_invit_mscpedu Clinical Case Scenarios in HR-Positive, HER2-Negative Early Breast Cancer: Assess the Risk of Recurrence and Eligibility for Adjuvant Therapy CME Clinical Case Scenarios in HR-Positive, HER2-Negative Early Breast Cancer: Assess the Risk of Recurrence and Eligibility for Adjuvant Therapy Authors: Seth Wander, MD, PhD; Manali Bhave, MD https://www.medscape.org/viewarticle/1002194?sso=true&uac=148436CN&src=mkmcmr_driv_invit_mscpedu Clinical Cases in HR-Positive, HER2-Negative Early Breast Cancer: Applying the Latest Evidence CME Clinical Cases in HR-Positive, HER2-Negative Early Breast Cancer: Applying the Latest Evidence Authors: William J. Gradishar, MD; Aditya Bardia, MD, MPH, FASCO; Seth Wander, MD, PhD https://www.medscape.org/viewarticle/1002256?sso=true&uac=148436CN&src=mkmcmr_driv_invit_mscpedu Navigating New Horizons in PNH and ITP: Perspectives for the Community CME Navigating New Horizons in PNH and ITP: Perspectives for the Community Authors: Sandra E. Kurtin, PhD, ANP-C, AOCN, FAPO; Cindy Neunert, MD, MSCS; Srikanth Nagalla, MD, MS https://www.medscape.org/viewarticle/navigating-new-horizons-pnh-and-itp-perspectives-community-2025a10004g2?page=1&sso=true&uac=148436CN&src=mkmcmr_driv_invit_mscpedu Determining the Risk of Recurrence in HR+/HER2- Early Breast Cancer Without Axillary Dissection CME Determining the Risk of Recurrence in HR+/HER2- Early Breast Cancer Without Axillary Dissection Authors: Sara M. Tolaney, MD, MPH; Elizabeth A. Mittendorf, MD, PhD, MHCM; Leah H. Portnow, MD https://www.medscape.org/viewarticle/1002279?sso=true&uac=148436CN&src=mkmcmr_driv_invit_mscpedu The Rise of Protein Degraders for Hematologic Malignancies: Exploring the Latest Data From ASH 2024 CME The Rise of Protein Degraders for Hematologic Malignancies: Exploring the Latest Data From ASH 2024 Authors: Sagar Lonial, MD, FACP; Constatine Tam, MBBS, MD, FRACP, FRCPath; Julio Chavez, MD, MS https://www.medscape.org/viewarticle/1002295?sso=true&uac=148436CN&src=mkmcmr_driv_invit_mscpedu Managing Adverse Events of Oral Adjuvant Therapies in Patients With HR+/HER2- Early Breast Cancer CME Managing Adverse Events of Oral Adjuvant Therapies in Patients With HR+/HER2- Early Breast Cancer Authors: Joyce A. O’Shaughnessy, MD https://www.medscape.org/viewarticle/managing-adverse-events-oral-adjuvant-therapies-patients-hr-2025a1000563?page=1&sso=true&uac=148436CN&src=mkmcmr_driv_invit_mscpedu